BNB Plus Corp. (NASDAQ: $BNBX) is adding new capital to its crypto-treasury overhaul as the Nasdaq-listed company tries to turn a small-cap balance sheet into a broader BNB (CRYPTO: $BNB) and digital-asset infrastructure strategy.
The company said it secured initial commitments for $4.1 million in convertible preferred stock financing, with additional commitments expected as it targets $5 million in total proceeds. The funds are expected to support BNB Plus’s digital asset treasury and provide working capital for a strategic review of its business, assets and capital structure.
BNB Plus expects to hold more than $16.4 million in cash and digital assets after the anticipated proceeds, based on values as of May 23. Investors include Comstock Multichain Fund, managed by Silvermine Capital Advisors, and other digital-asset-focused institutional backers, including Off the Chain, LP.
More From Cryptoprowl:
The financing also brings GlobalStake Infrastructure into the process. The SOC 2 Type II certified Web3 infrastructure company is expected to lead the review, which will assess both digital asset opportunities and the future of LineaRx, BNB Plus’s biotechnology subsidiary.
That split is the center of the story. BNB Plus, formerly Applied DNA Sciences, has been repositioning around Binance’s BNB ecosystem while still carrying a biotech asset that could be monetized through partnerships, licensing, asset sales or other transactions. The digital asset side of the review will look at institutional yield generation and the overlap between agentic AI and crypto payment mechanisms.
CEO Clay Shorrock said the financing reflects investor confidence in BNBX’s operating trajectory and value proposition, pointing to a reduced cost structure and recent profitability at LineaRx in fiscal Q2.
The financing includes Series B-1 preferred stock priced at $1.05 per share, a 176% premium to the company’s May 22 closing price, and Series B-2 preferred stock priced at $0.38 per share.
BNB Plus Corp. (NASDAQ: BNBX) is currently trading at $0.378 U.S. per share.
